Navigation Links
Cordis Unveils Next Generation CoCr Coronary Stent
Date:3/11/2010

WATERLOO, Belgium, March 11, 2010 /PRNewswire/ --

- PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries

Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances designed to gain easier access to distal lesions and help restore the artery's natural form.

"The new upgraded delivery system increases the speed of procedures with atraumatic delivery, increased pushability, and smoother withdrawal. We are very satisfied with the speed in which we were able to incorporate feedback from cardiologists into the new design," said Campbell Rogers MD, Global Head of R&D of Cordis Corporation.

The PRESILLION(TM) PLUS changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time.

The PRESILLION(TM) PLUS stent is available in lengths from 8 to 33mm including a new 28mm addition and in diameters from 2.5 to 4.0mm.

The PIONIR study, designed to measure the safety and effectiveness of PRESILLION(TM) and PRESILLION(TM) PLUS, completed enrollment at 16 sites in Europe and Israel. The study, conducted by Medinol, includes 278 patients and will evaluate clinical performance through one year.

"Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. The new PRESILLION(TM) PLUS further complements our portfolio with its technological advances. We will continue to deliver innovative new solutions that save lives and improve the quality of life for people around the world," said Staffan Ternstrom, President, Cordis Europe, Middle-East, Africa.

Cordis Corporation is the exclusive global distributor of PRESILLION(TM) PLUS, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION (TM) PLUS is a trademark of Cordis Corporation.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.

Cordis Corporation signed an exclusive distribution agreement with Medinol in 2008 and will be distributing PRESILLION (TM) PLUS globally. Medinol is a stent innovation company that develops both stents and delivery systems through design innovation and advanced manufacturing technologies.

    Media Contacts: Isabella Sharp
    APCO Worldwide
    isharp@apcoworldwide.com
    +44(0)20-7526-3632
    +44(0)7813-307490


SOURCE Cordis Corporation

Back to top
'/>"/>
SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting
2. FamilyCord Unveils Safer and More Effective Cord Blood Collection Kit
3. Quest Diagnostics Unveils Care360(TM) EHR
4. FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging
5. Slovenias Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB
6. Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use
7. National Expressions of Courage Art Contest Unveils Stories of Inspiration
8. Aflex Unveils Revolutionary New Hose Design for the Chemical and Process Industry
9. Siemens Unveils New Hearing Loss Options at SPLASH: ADAs 2009 Convention
10. Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress
11. Eurotech Unveils New Diabetes Care Management Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):